Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
A clinical-stage immunology company focused on infectious diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo takes on rare liver virus in head-to-head trial Results expected Nov 2026 (estimated)
- New drug combo aims to tackle stubborn hepatitis d Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New drug duo aims to control hard-to-treat hepatitis delta Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hepatitis b: experimental drug shows promise in mid-stage trial
Disease control CompletedThis study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for hepatitis b: experimental combo aims to silence the virus
Disease control CompletedThis early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…
Phase 1/2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can two experimental drugs be used safely in people with cirrhosis?
Knowledge-focused CompletedResearchers are studying how the body handles two experimental drugs, VIR-2218 and VIR-3434, in adults with cirrhosis and liver impairment. Participants receive a single injection of one drug or both together. The trial measures drug levels in the blood and checks for side effect…
Phase 1 • Sponsor: Vir Biotechnology, Inc. • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC